NEOS Investment Management LLC Sells 26,990 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

NEOS Investment Management LLC decreased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 60.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 17,693 shares of the company’s stock after selling 26,990 shares during the quarter. NEOS Investment Management LLC’s holdings in Mirum Pharmaceuticals were worth $732,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in MIRM. Jones Financial Companies Lllp grew its stake in Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after buying an additional 357 shares during the last quarter. R Squared Ltd acquired a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $69,000. AlphaQuest LLC raised its position in Mirum Pharmaceuticals by 969.6% in the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after purchasing an additional 1,658 shares during the last quarter. Avanza Fonder AB acquired a new position in Mirum Pharmaceuticals in the fourth quarter worth $189,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Mirum Pharmaceuticals during the third quarter worth $215,000.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 7,879 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $348,330.59. Following the transaction, the chief operating officer now directly owns 18,672 shares in the company, valued at approximately $825,489.12. The trade was a 29.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Christopher Peetz sold 7,489 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the sale, the chief executive officer now owns 119,359 shares of the company’s stock, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 133,679 shares of company stock worth $6,007,081. 22.87% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $45.99 on Monday. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $54.23. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -22.77 and a beta of 1.04. The firm has a fifty day moving average of $48.01 and a two-hundred day moving average of $43.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The company had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. As a group, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on MIRM. HC Wainwright lifted their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a report on Friday, February 28th. Robert W. Baird upped their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $58.20.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.